Mechanism of catheter thrombosis: Comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo

Blood

Volumn 118, Issue 25, 2011, Pages 6667-6674

  Yau, Jonathan W ^a   Stafford, Alan R ^a   Liao, Peng ^a   Fredenburgh, James C ^a   Roberts, Robin ^a   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 9A; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; RECOMBINANT THROMBOPLASTIN; THROMBIN; TRYPSIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CATHETER THROMBOSIS; CONTROLLED STUDY; INTRAVASCULAR CATHETER; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

EID: 84055218954     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-364141     Document Type: Article

References (35)

1. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45-54.
2. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355(10):1006-1017. (Pubitemid 44343544)
3. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695-1702.
4. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867-873.
5. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res. 2003;109(1):1-11. (Pubitemid 36385042)
6. Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol. 2010;3(5):567-581.
7. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-1476.
8. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519- 1530.
9. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50(18):1742-1751. (Pubitemid 47600591)
10. Berg TA, Galdonik JA, inventors; Boston Scientific Scimed, assignee. Guide catheter having selected flexural modulus segments. Minnesota, US patent 7674411. September 10, 2010.
11. Visser A, Meuleman DG. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans. Thromb Res. 1990;58(5):469-479. (Pubitemid 20218202)
12. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359(7):688-696.
13. Du YJ, Klement P, Berry LR, Tressel P, Chan AK. In vivo rabbit acute model tests of polyurethane catheters coated with a novel antithrombin-heparin covalent complex. Thromb Haemost. 2005;94(2):366-372. (Pubitemid 41122492)
14. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(6 Suppl):708S-775S. (Pubitemid 351892976)
15. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(6 Suppl):670S-707S. (Pubitemid 351892975)
16. Amar J, Caranobe C, Sie P, Boneu B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit. Br J Haematol. 1990;76(1):94-100. (Pubitemid 20326801)
17. Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res. 1980;20(2):149-162. (Pubitemid 11174769)
18. Wiebe EM, Stafford AR, Fredenburgh JC, Weitz JI. Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J Biol Chem. 2003;278(37):35767-35774. (Pubitemid 37102353)
19. Vogler EA, Siedlecki CA. Contact activation of blood-plasma coagulation. Biomaterials. 2009;30(10):1857-1869.
20. Tankersley DL, Alving BM, Finlayson JS. Activation of factor XII by dextran sulfate: the basis for an assay of factor XII. Blood. 1983;62(2):448-456. (Pubitemid 13036098)
21. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A. 2006;103(4):903-908. (Pubitemid 43212194)
22. Tans G, Griffin JH. Properties of sulfatides in factor-XII-dependent contact activation. Blood. 1982;59(1):69-75. (Pubitemid 12162347)
23. Schmaier AH, McCrae KR. The plasma kallikreinkinin system: its evolution from contact activation. J Thromb Haemost. 2007;5(12):2323-2329. (Pubitemid 350154338)
24. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007;104(15):6388-6393. (Pubitemid 47186104)
25. van der Kamp KW, Hauch KD, Feijen J, Horbett TA. Contact activation during incubation of five different polyurethanes or glass in plasma. J Biomed Mater Res. 1995;29(10):1303-1306.
26. Bernacca GM, Gulbransen MJ, Wilkinson R, Wheatley DJ. In vitro blood compatibility of surface-modified polyurethanes. Biomaterials. 1998;19(13):1151-1165. (Pubitemid 28388832)
27. van der Kamp KW, van Oeveren W. Factor XII fragment and kallikrein generation in plasma during incubation with biomaterials. J Biomed Mater Res. 1994;28(3):349-352.
28. Cenni E, Ciapetti G, Cervellati M, et al. Activation of the plasma coagulation system induced by some biomaterials. J Biomed Mater Res. 1996;31(1):145-148. (Pubitemid 26125314)
29. Zhuo R, Siedlecki CA, Vogler EA. Autoactivation of blood factor XII at hydrophilic and hydrophobic surfaces. Biomaterials. 2006;27(24):4325-4332. (Pubitemid 43674176)
30. Arvidsson S, Askendal A, Tengvall P. Blood plasma contact activation on silicon, titanium and aluminium. Biomaterials. 2007;28(7):1346-1354. (Pubitemid 44959039)
31. Beathard GA. Catheter thrombosis. Semin Dial. 2001;14(6):441-445. (Pubitemid 33720889)
32. Schlitt A, Rupprecht HJ, Reindl I, et al. In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. Coron Artery Dis. 2008;19(4):279-284.
33. Buller CE, Pate GE, Armstrong PW, et al. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol. 2006;22(6):511-515.
34. Chen H, Zhang Y, Li D, et al. Surfaces having dual fibrinolytic and protein resistant properties by immobilization of lysine on polyurethane through a PEG spacer. J Biomed Mater Res A. 2009;90(3):940-946.
35. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304(12):1339-1349.